Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Pierre Pouget

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
Theranostics|October 8, 2019
Pretargeted radioimmunotherapy and SPECT imaging of peritoneal carcinomatosis using bioorthogonal click chemistry: probe selection and first proof-of-conceptAurélie Rondon, Sébastien Schmitt, Arnaud Briat, et al.
Scientific Reports|November 4, 2017
Antibody PEGylation in bioorthogonal pretargeting with trans-cyclooctene/tetrazine cycloaddition: in vitro and in vivo evaluation in colorectal cancer modelsAurélie Rondon, Nancy Ty, Jean-Baptiste Bequignat, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 19, 2023
Gadolinium-Based Nanoparticles Sensitize Ovarian Peritoneal Carcinomatosis to Targeted Radionuclide TherapyClara Diaz Garcia-Prada, Léna Carmes, Salima Atis, et al.
Investigational New Drugs|April 3, 2014
Evaluation of two (125)I-radiolabeled acridine derivatives for Auger-electron radionuclide therapy of melanomaMaryline Gardette, Claire Viallard, Salomé Paillas, et al.
Leukemia|December 15, 2019
The therapeutic effectiveness of <sup>177</sup>Lu-lilotomab in B-cell non-Hodgkin lymphoma involves modulation of G2/M cell cycle arrestAlexandre Pichard, Sara Marcatili, Jihad Karam, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 21, 2018
Radiolabeled Antibodies Against Müllerian-Inhibiting Substance Receptor, Type II: New Tools for a Theranostic Approach in Ovarian CancerEmmanuel Deshayes, Riad Ladjohounlou, Pierre Le Fur, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2019
Drugs That Modify Cholesterol Metabolism Alter the p38/JNK-Mediated Targeted and Nontargeted Response to Alpha and Auger RadioimmunotherapyRiad Ladjohounlou, Catherine Lozza, Alexandre Pichard, et al.
Oncotarget|April 21, 2017
Tetraspanin 8 (TSPAN 8) as a potential target for radio-immunotherapy of colorectal cancerAurelie Maisonial-Besset, Tiffany Witkowski, Isabelle Navarro-Teulon, et al.
Oncotarget|April 22, 2017
The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cellsPauline Estupina, Alexandre Fontayne, Jean-Marc Barret, et al.
Oncoimmunology|December 19, 2024
Pushing the boundaries of radiotherapy-immunotherapy combinations: highlights from the 7<sup>th</sup> immunorad conferencePierre-Antoine Laurent, Fabrice André, Alexandre Bobard, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
Theranostics|October 8, 2019
Pretargeted radioimmunotherapy and SPECT imaging of peritoneal carcinomatosis using bioorthogonal click chemistry: probe selection and first proof-of-conceptAurélie Rondon, Sébastien Schmitt, Arnaud Briat, et al.
Scientific Reports|November 4, 2017
Antibody PEGylation in bioorthogonal pretargeting with trans-cyclooctene/tetrazine cycloaddition: in vitro and in vivo evaluation in colorectal cancer modelsAurélie Rondon, Nancy Ty, Jean-Baptiste Bequignat, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 19, 2023
Gadolinium-Based Nanoparticles Sensitize Ovarian Peritoneal Carcinomatosis to Targeted Radionuclide TherapyClara Diaz Garcia-Prada, Léna Carmes, Salima Atis, et al.
Investigational New Drugs|April 3, 2014
Evaluation of two (125)I-radiolabeled acridine derivatives for Auger-electron radionuclide therapy of melanomaMaryline Gardette, Claire Viallard, Salomé Paillas, et al.
Leukemia|December 15, 2019
The therapeutic effectiveness of <sup>177</sup>Lu-lilotomab in B-cell non-Hodgkin lymphoma involves modulation of G2/M cell cycle arrestAlexandre Pichard, Sara Marcatili, Jihad Karam, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 21, 2018
Radiolabeled Antibodies Against Müllerian-Inhibiting Substance Receptor, Type II: New Tools for a Theranostic Approach in Ovarian CancerEmmanuel Deshayes, Riad Ladjohounlou, Pierre Le Fur, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2019
Drugs That Modify Cholesterol Metabolism Alter the p38/JNK-Mediated Targeted and Nontargeted Response to Alpha and Auger RadioimmunotherapyRiad Ladjohounlou, Catherine Lozza, Alexandre Pichard, et al.
Oncotarget|April 21, 2017
Tetraspanin 8 (TSPAN 8) as a potential target for radio-immunotherapy of colorectal cancerAurelie Maisonial-Besset, Tiffany Witkowski, Isabelle Navarro-Teulon, et al.
Oncotarget|April 22, 2017
The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cellsPauline Estupina, Alexandre Fontayne, Jean-Marc Barret, et al.
Oncoimmunology|December 19, 2024
Pushing the boundaries of radiotherapy-immunotherapy combinations: highlights from the 7<sup>th</sup> immunorad conferencePierre-Antoine Laurent, Fabrice André, Alexandre Bobard, et al.
Pageof 7